IRIS
DE LAURENTIIS, MICHELINO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 11.495
NA - Nord America 8.610
EU - Europa 6.659
SA - Sud America 1.271
AF - Africa 244
OC - Oceania 13
Continente sconosciuto - Info sul continente non disponibili 2
Totale 28.294
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.212
SG - Singapore 5.035
RU - Federazione Russa 2.801
CN - Cina 2.240
VN - Vietnam 1.812
HK - Hong Kong 1.106
IT - Italia 1.045
BR - Brasile 983
NL - Olanda 635
DE - Germania 588
FR - Francia 359
FI - Finlandia 305
BD - Bangladesh 236
IN - India 232
CA - Canada 215
GB - Regno Unito 199
JP - Giappone 196
IE - Irlanda 189
UA - Ucraina 189
KR - Corea 139
AR - Argentina 121
MX - Messico 97
SE - Svezia 81
ZA - Sudafrica 76
AT - Austria 67
IQ - Iraq 65
ID - Indonesia 52
PH - Filippine 45
PL - Polonia 45
TH - Thailandia 45
PK - Pakistan 43
EC - Ecuador 41
CI - Costa d'Avorio 40
ES - Italia 36
CO - Colombia 34
TR - Turchia 34
TW - Taiwan 28
VE - Venezuela 25
JO - Giordania 23
CL - Cile 22
PY - Paraguay 22
NP - Nepal 21
TN - Tunisia 20
UZ - Uzbekistan 20
JM - Giamaica 19
SA - Arabia Saudita 16
CZ - Repubblica Ceca 15
KE - Kenya 15
MA - Marocco 15
EG - Egitto 14
LT - Lituania 13
BE - Belgio 11
DO - Repubblica Dominicana 11
DZ - Algeria 11
MY - Malesia 10
CH - Svizzera 9
ET - Etiopia 9
GT - Guatemala 9
IL - Israele 9
IR - Iran 9
KZ - Kazakistan 9
PE - Perù 9
UY - Uruguay 9
AU - Australia 8
HN - Honduras 8
AE - Emirati Arabi Uniti 7
AL - Albania 7
LV - Lettonia 7
RO - Romania 7
BH - Bahrain 6
CR - Costa Rica 6
GE - Georgia 6
LB - Libano 6
MD - Moldavia 6
NG - Nigeria 6
TT - Trinidad e Tobago 6
AM - Armenia 5
BZ - Belize 5
HR - Croazia 5
OM - Oman 5
PS - Palestinian Territory 5
SN - Senegal 5
BA - Bosnia-Erzegovina 4
BG - Bulgaria 4
BY - Bielorussia 4
KH - Cambogia 4
LA - Repubblica Popolare Democratica del Laos 4
NI - Nicaragua 4
NO - Norvegia 4
PA - Panama 4
AO - Angola 3
AZ - Azerbaigian 3
BO - Bolivia 3
BS - Bahamas 3
CG - Congo 3
LK - Sri Lanka 3
ME - Montenegro 3
MN - Mongolia 3
NZ - Nuova Zelanda 3
TJ - Tagikistan 3
Totale 28.219
Salva come PNG Salva come JPEG
Città #
Singapore 2.524
San Jose 1.498
Hong Kong 1.077
Moscow 712
Hefei 682
Ashburn 619
Amsterdam 577
Beijing 541
Ho Chi Minh City 494
Secaucus 458
Chandler 454
Hanoi 413
Santa Clara 369
Millbury 269
The Dalles 254
Lauterbourg 244
Los Angeles 235
Munich 224
Naples 182
Tokyo 182
Jacksonville 162
Princeton 156
Dallas 150
Buffalo 138
New York 125
Nanjing 118
Seoul 118
Redondo Beach 114
Dong Ket 98
Helsinki 93
Napoli 92
Wilmington 91
São Paulo 88
Boston 82
Des Moines 76
Kochi 75
Council Bluffs 73
Frankfurt am Main 68
Nuremberg 68
Ottawa 68
Milan 62
Haiphong 61
Da Nang 60
Turku 57
Montreal 52
Seattle 52
Mexico City 50
Orem 50
Chicago 47
Lawrence 47
Toronto 45
Nanchang 43
Brooklyn 42
Rome 42
Houston 41
Johannesburg 40
Dublin 36
London 33
Warsaw 33
Stockholm 32
Chennai 30
Rio de Janeiro 29
Baghdad 28
Denver 28
Tianjin 28
Belo Horizonte 27
Hebei 26
San Francisco 26
Atlanta 24
Pune 24
Falkenstein 23
Hải Dương 23
Phoenix 23
Poplar 23
Shenyang 23
Biên Hòa 22
Brasília 22
Dhaka 22
Jiaxing 22
Vienna 22
Bangkok 21
Ninh Bình 21
Norwalk 21
Amman 20
Can Tho 20
Tashkent 20
Boardman 19
Changsha 17
Charlotte 17
Salerno 17
Shanghai 17
Porto Alegre 16
Falls Church 15
Manchester 15
Nairobi 15
Quito 15
Bologna 14
Bắc Ninh 14
Guayaquil 14
Salvador 14
Totale 15.823
Salva come PNG Salva come JPEG
Nome #
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years 1.054
Glucose impairs tamoxifen responsiveness modulating connective tissue growth factor in breast cancer cells 264
Manuale di Oncologia Clinica 234
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: A survey of young oncologists 195
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer 189
Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology. 180
CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. 179
A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer. 178
Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy 173
Mediterranean diet and quality of life in women treated for breast cancer: A baseline analysis of DEDiCa multicentre trial 172
The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer. 163
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer 162
Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations 159
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial 158
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. 155
Adipose microenvironment promotes triple negative breast cancer cell invasiveness and dissemination by producing CCL5 155
Combined effect of obesity and diabetes on early breast cancer outcome: A prospective observational study 155
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: An open-label, 2 × 2 factorial, randomised phase 3 trial 153
Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study 153
Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU. A phase 2 study. 152
Low glycemic index diet, exercise and vitamin D to reduce breast cancer recurrence (DEDiCa): design of a clinical trial 150
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study 149
Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. 146
Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results 145
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials 143
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype 143
Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study. 142
Body weight and risk of molecular breast cancer subtypes among postmenopausal Mediterranean women 141
Warming-up the immune cell engagers (ICEs) era in breast cancer: state of the art and future directions 139
Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: a randomized placebo-controlled trial 136
An interaction network approach to study the correlation between endocrine disrupting chemicals and breast cancer 136
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis 136
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI) 136
Molecular profiles of screen detected vs. symptomatic breast cancer and their impact on survival: results from a clinical series 135
Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis 135
CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study). 134
alpha-Interferon potentiates the growth inhibitory effects of anti-transferrin receptor monoclonal antibodies 133
Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patients 132
Contrast-enhanced harmonic compound US of the spleen to increase staging accuracy in patients with Hodgkin lymphoma: a prospective study. 132
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer 131
Central obesity, body mass index, metabolic syndrome and mortality in Mediterranean breast cancer patients 130
Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab. 130
Unexpected ovarian activity in premenopausal breast cancer survivors treated with exemestane and GnRH analogues 130
Castalin Induces ROS Production, Leading to DNA Damage and Increasing the Activity of CHK1 Inhibitor in Cancer Cell Lines 130
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 129
Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis 128
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials 127
Prognostic Value of Cancer Stem Cells Markers in Triple-Negative Breast Cancer 127
Phase I-II study of xelox and bevacizumab plus erlotinib in sequential combination (XELOX-TARAV) in first line colorectal cancer: run in part 125
Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial 125
Amyloid in bone marrow smears of patients affected by multiple myeloma. 124
Oleanolic Acid Modulates DNA Damage Response to Camptothecin Increasing Cancer Cell Death 123
Inhibition of autophagy by chloroquine prevents resistance to PI3K/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer models 123
C-erbB2 overexpression decreases the benefit of adiuvant tamoxifen in early breast cancer without axillary lymph node metastases. 122
Vinorelbine + mitomycin C as second-line treatment of metastatic breast cancer: a two-stage phase 2 study. 122
A-Interferon potentiates the growth inhibitory effects of anti-transferrin receptor monoclonal antibodies. 122
Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients. 122
Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. 121
A Psychosocial Genomics Pilot Study in Oncology for Verifying Clinical, Inflammatory and Psychological Effects of Mind-Body Transformations-Therapy (MBT-T) in Breast Cancer Patients: Preliminary Results 121
High progesterone levels during the luteal phase related to the use of an aromatase inhibitor in breast cancer patients 120
Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial 120
A Metanalysis on the Interaction between HER2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer 119
Metabolic syndrome-breast cancer link varies by intrinsic molecular subtype 119
Endocrine‐based treatments in clinically‐relevant subgroups of hormone receptor‐positive/her2‐negative metastatic breast cancer: Systematic review and meta‐analysis 119
Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial 118
Expression of biomarkers modulating prostate cancer progression: Implications in the treatment of the disease 118
Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer 117
CD10/common acute lymphoblastic leukemia-associated antigen and adhesion factor expression is predictive for lymphokine-activated killing sensitivity of adult B-lineage acute lymphoblastic leukemia 117
Targeting cell cycle in breast cancer: CDK4/6 inhibitors 116
Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials 116
Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients 116
Trastuzumab Emtansine plus Pertuzumab Versus Taxane plus Trastuzumab plus Pertuzumab after Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study 115
Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)': [ESMO Open Volume 6, Issue 2, April 2021, 100054] 115
Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies 115
A Feasibilty Study of a Sequential Dose-Dense Adjuvant Regimen with Epidoxorubicin Followed by Docetaxel Followed by High-Dose Cyclophosphamide for Early Breast Cancer with 4 or More Lymph Node Metastases. 115
Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2− Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study 113
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study 112
Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-lerm follow-up. 112
Is there a standard chemotherapeutic regimen for hormone-refractory prostate cancer? Present and future approaches in the management of the disease. 111
Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. 110
Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time? 110
Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. 109
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. 109
HER2 as predictive marker of resistance to endocrine treatment for advanced bresat cancer: a metanalysis of published studies 109
Virtual reality and music therapy as distraction interventions to alleviate anxiety and improve mood states in breast cancer patients during chemotherapy 109
The clinical and translational research activities at the INT – IRCCS “Fondazione Pascale” cancer center (Naples, Italy) during the COVID-19 pandemic 108
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. 108
Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study 108
Efficacy and Safety of Trastuzumab Emtansine plus Capecitabine vs Trastuzumab Emtansine Alone in Patients with Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 Trial 108
Estrogen deprivation effects of endocrine therapy in breast cancer patients: Incidence, management and outcome 107
Uptake of trastuzumab biosimilars for the treatment of her2-positive breast cancer: A real-world experience from a cancer center 107
Prognostic significance of necrosis, elestosis, fibrosis and inflammatory cell reaction in operable breast cancer. 107
Mitoxantrone, etoposide and bleomycin (MEB) chemotherapy in non-Hodgkin's Lymphoma patients non-elegible for standard cyclophosphamide, doxorubicin vincristine and prednisone (CHOP) combination. 107
Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. 106
TAG-72 expression and clinical outcome in primary breast cancer. 106
New steps on an old path: Novel estrogen receptor inhibitors in breast cancer 105
Chemotherapy with mitomycin C and vinblastine in pretreated metastatic breast cancer. 105
Neratinib as adjuvant therapy in patients with HER2 positive breast cancer: expert opinion 105
Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial 104
Long-term complete response with third-line PARP inhibitor after immunotherapy in a patient with triple-negative breast cancer: a case report 104
Totale 14.112
Salva come PNG Salva come JPEG
Categoria #
all - tutte 91.059
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 91.059
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.110 9 4 10 4 21 50 15 45 175 90 202 485
2022/20231.339 224 95 38 79 129 123 12 80 189 248 100 22
2023/20241.156 43 166 161 77 50 79 13 81 12 22 198 254
2024/20257.458 457 582 42 75 150 343 752 490 791 821 2.276 679
2025/202615.588 1.507 1.765 1.505 1.294 2.221 944 1.572 1.035 1.915 927 400 503
2026/2027158 158 0 0 0 0 0 0 0 0 0 0 0
Totale 28.735